Northern Trust
ADAP

Northern Trust’s Adaptimmune Therapeutics ADAP Stock Holding History

Northern Trust’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,584
Closed -$6.32K – 4450
2025
Q3 		$6.32K Sell
48,584
-2,749
-5% -$377 ﹤0.01% 4415
2025
Q2 		$12.3K Hold
51,333
– – ﹤0.01% 4368
2025
Q1 		$10.1K Hold
51,333
– – ﹤0.01% 4386
2024
Q4 		$27.7K Hold
51,333
– – ﹤0.01% 4345
2024
Q3 		$48.8K Sell
51,333
-528
-1% -$599 ﹤0.01% 4216
2024
Q2 		$50.6K Sell
51,861
-5,639
-10% -$6.19K ﹤0.01% 4213
2024
Q1 		$90.8K Buy
57,500
+77
+0.1% +$93 ﹤0.01% 4103
2023
Q4 		$45.5K Hold
57,423
– – ﹤0.01% 4251
2023
Q3 		$44.8K Sell
57,423
-1,346
-2% -$1.13K ﹤0.01% 4194
2023
Q2 		$54.4K Buy
+58,769
New +$70.1K ﹤0.01% 4203
2021
Q1 		– Sell
-50,000
Closed -$270K – 4473
2020
Q4 		$270K Buy
+50,000
New +$272K ﹤0.01% 3895

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.41B AUM 41.48% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Northern Trust's ADAP Position: Q4 2025 in Review

Northern Trust sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 48,584 shares — an estimated $6.32K sold.

Northern Trust first reported a position in ADAP in Q4 2020 and held it in 11 quarters. The position peaked at $270K in Q4 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Northern Trust reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Northern Trust sold 48,584 Adaptimmune Therapeutics shares in Q4 2025, an estimated $6.32K.
  • Northern Trust first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 11 quarters.
  • Northern Trust's Adaptimmune Therapeutics position peaked at $270K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Northern Trust's 13F filing for Q4 2025, filed 17 Feb 2026.